Orgenesis announces results for study of CD19 CAR-T therapy

Written by Emily J. Thompson, Senior Investment Analyst

ORGS%

Updated: Aug 29 2024

0mins

Positive Clinical Trial Results: Orgenesis reported successful outcomes from a clinical trial of its CD19 CAR-T therapy, ORG-101, showing an 82% complete response rate in adults and 93% in pediatric patients with CD19+ Acute Lymphoblastic Leukemia.
Safety Profile: The therapy demonstrated a low incidence of severe Cytokine Release Syndrome (2% in adults and 6% in children), indicating a favorable safety profile compared to existing CAR-T treatments.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Orgenesis announces results for study of CD19 CAR-T therapy

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Top Growth Stocks to Buy Now: Nvidia, Amazon, Dutch Bros

Bitcoin's Market Cap Exceeds $1.9 Trillion, Potential to Reach $1.2 Million

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch